MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1
Authors: Pengfei Lei
Yingying Zhang
Zijian Zhang
Xucheng Yang
Yong Huang
Journal: Oncology Letters (2016)
Discipline: CLINICAL MEDICINE
Keywords: fascin1; invasion; microRNA-133b; migration; non small cell lung cancer.
Affiliations: Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China., Department of Oncology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China.

Abstract:  MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple types of human cancers, including non small cell lung cancer (NSCLC). However, the underlying mechanism by which miR-133b inhibits NSCLC metastasis remains largely unclear. In the present study, reverse transcription-quantitative polymerase chain reaction and western blotting were used to detect messenger RNA and protein expression. A wound healing assay and transwell assay were used to examine the cell migration and invasion. The expression level of miR-133b was found to be significantly downregulated in NSCLC cell lines compared with normal lung epithelial BEAS-2B cells. Further investigation identified fascin1 (FSCN1) as a direct target of miR-133b in NSCLC cells. The expression of FSCN1 was significantly increased in NSCLC cell lines compared with BEAS-2B cells, and its protein expression was negatively regulated by miR-133b in NSCLC A549 cells. Further investigation showed that the upregulation of miR-133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, the overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion. Accordingly, the present study suggests that miR-133b inhibits the migration and invasion of NSCLC cells via directly targeting FSCN1, and thus may be used for the treatment of NSCLC metastasis. 

Retracted: Yes

PubPeer comments:
 Fig 4B.  Wound healing assays were conducted to examine the cell migration capacities of A549 cells transfected with (A) miR-133b mimics and **(B) FSCN1 plasmids** . ![file] Panel shared with Fig 3A of [Jiang et al (2016)] . ![] ------------------------------------------------------------------------- Fig 5B.  A wound healing assay ... were conducted to examine the cell migration ... in each group. ![file] Fig 4 of [Yang et al (2016a)] . ![file] Fig 5A from [Wang et al (2016)] .  Wound healing assay to determine the migratory capacity of U2OS cells transfected with miR-101 mimics or c-FOS siRNA, or co-transfected with miRu2011101 mimics and cu2011FOS plasmid . ![file] , 
 *[upper]* Figs 4 C D and 5C.  Transwell assays were conducted to examine the cell invasion capacities ofA549 cells transfected with (C) miR-133b mimics and (D) FSCN1 plasmids. Non-transfected A549 cells were used as control ...  Transwell assay were conducted to examine the cell migration and invasion in each group , *[lower]* Fig 5B from [Wang et al (2016).  Transwell assay to determine the invasive capacity of U2OS cells transfected with miRu2011101 mimics or cu2011FOS siRNA, or cou2011transfected with miRu2011101 mimics and cu2011FOS plasmid. Magnification, x100. Control: untransfected U2OS cells . ![] --------------------------------------- Update: Fig 7 from [Wang et al (2014)] . ![] , 
 Retracted [15 June 2021] . --------------------------------- Following the publication of this paper, it was drawn to the Editorsu2019 attention by a concerned reader that the scratchu2011wound assay data shown in Figs. 4B and 5B were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to *Oncology Letters*, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. ,